Last reviewed · How we verify
Zonegran
At a glance
| Generic name | Zonegran |
|---|---|
| Also known as | zonisamide |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Target | Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Diffuse Lewy body disease
- Partial Epilepsy Treatment Adjunct
Common side effects
- Somnolence
- Anorexia
- Dizziness
- Ataxia
- Agitation/Irritability
- Difficulty with memory and/or concentration
- Fatigue
- Nausea/Vomiting
- Weight loss
- Mental slowing
- Accidental injury
- Asthenia
Serious adverse events
- Lupus erythematosus
- Pulmonary embolus
- Heart failure
- Atrial fibrillation
- Thrombocytopenia
- Cholestatic jaundice
- Hematemesis
- Hyponatremia
- Syncope
- Thrombophlebitis
Key clinical trials
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (PHASE3)
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |